Wave II clinical study will evaluate THRV-1268, Thryv's oral SGK1 inhibitor, in adults with Long QT Syndrome Type 2. Wave II is informed by the successful Wave I clinical study with LQT-1213 and ...
MONTREAL, Oct. 15, 2024 /PRNewswire/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company, received positive top-line results from the Wave I Part 2 proof-of-concept clinical study ...
The MarketWatch News Department was not involved in the creation of this content. -- Wave II clinical study will evaluate THRV-1268, Thryv's oral SGK1 inhibitor, in adults with Long QT Syndrome Type 2 ...
The MarketWatch News Department was not involved in the creation of this content. -- Wave II clinical study will evaluate THRV-1268, Thryv's oral SGK1 inhibitor, in adults with Long QT Syndrome Type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results